• Explore /
  • Poster
  • / Sudocetaxel zendusortide (TH1902), a novel sortilin-receptor (SORT1)-targeting peptide-drug-conjugate (PDC) in patients (pts) with advanced solid tumors: Results from part 1 (dose-escalation) of a phase 1, open-label study.

Sudocetaxel zendusortide (TH1902), a novel sortilin-receptor (SORT1)-targeting peptide-drug-conjugate (PDC) in patients (pts) with advanced solid tumors: Results from part 1 (dose-escalation) of a phase 1, open-label study.

Abstract Poster

Authors

null

Funda Meric-Bernstam

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX

Funda Meric-Bernstam , Satish Shah , Manish Sharma , Annick Metcalfe , Guylaine Roy , Lynn Marie Douglas , Christian Marsolais , Ira Seth Winer

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Track

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Sub Track

New Targets and New Technologies (non-IO)

Clinical Trial Registration Number

NCT04706962

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 3089)

DOI

10.1200/JCO.2023.41.16_suppl.3089

Abstract #

3089

Poster Bd #

287

Abstract Disclosures

Similar Posters

First Author: Vivek Subbiah

First Author: Serena Marchetti

First Author: Soohyeon Lee

First Author: Jessica Dreger McDermott